TB-500 and Thymosin Beta-4: The Most Comprehensive Research Map Yet (2026)
TB500 and Thymosin Beta4: The Most Comprehensive Research Map Yet (2026) Background Thymosin beta4 (TB4) is a 43aminoacid peptide and the most abundant betathymosin in the human body. It plays a central role in actin sequestration — regulating the pool of free Gactin available for cell motility, wound closure, and tissue remodeling. TB500 is a commercially used designation for synthetic peptide products marketed as related to TB4, though the exact relationship between TB500 products and native TB4 varies across manufacturers. Despite widespread use in athletic recovery and regenerative medicine communities, no comprehensive scoping review had previously mapped the full TB4/TB500 literature. That changed in June 2026 with the publication of a PRISMAcompliant scoping review in Applied Sciences by researchers at the University of Utah (McGuire et al., doi: 10.3390/app16126202). What the Review Found The review screened 1,772 records and included 80 studies. Several patterns emerged that are important for anyone following this area of research. The evidence base is weighted toward TB4, not TB500. The vast majority of included studies evaluated native thymosin beta4. Direct evidence specifically for TB500 as a commercial product was limited to a single included study — a significant finding given how prominently TB500 is marketed. Tissue coverage is uneven. The most studied tissue categories were: Wound/skin/soft tissue Vascular/endothelial Ocular/cornea Bone Direct musculoskeletal categories — tendon, ligament, muscle, cartilage, and intervertebral disc — were comparatively sparse. This is notable because musculoskeletal recovery is the primary use case promoted for TB500 in athletic and fitness communities. Human evidence is concentrated in specific areas. Human clinical data exists primarily in ocular/corneal and wound/skin healing contexts. There is very limited human evidence for the musculoskeletal applications most commonly promoted. Mechanisms of Action TB4's biological activity is primarily mediated through its actinsequestering Nterminal domain (the tetrapeptide AcSDKP) and its ability to promote: Cell migration and proliferation — TB4 binds Gactin and regulates cytoskeletal dynamics, enabling faster wound closure and tissue remodeling Angiogenesis — TB4 promotes the formation of new blood vessels, supporting nutrient delivery to injured tissue Antiinflammatory signaling — TB4 inhibits NFκB activation and reduces proinflammatory cytokine production Cardiac protection — Some of the strongest humanadjacent evidence for TB4 comes from cardiac contexts, where it has been studied for myocardial repair following infarction Regulatory Context The World AntiDoping Agency classifies TB4 and its derivatives — including TB500 — as prohibited substances under the 2026 Prohibited List. The FDA lists the TB4 fragment LKKTETQ among bulk drug substances that may present significant safety risks in compounding due to limited human exposure data. In July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed TB500 alongside six other peptides as part of a broader assessment of whether these compounds should be eligible for legal compounding under Section 503A of the Federal Food, Drug and Cosmetic Act. What This Means for Researchers The 2026 scoping review is valuable precisely because it distinguishes between what is biologically plausible, what is preclinically supported, and what has actually been demonstrated in humans. The authors conclude that the mapped literature "supports the popular interest in several repairrelated pathways but remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications." For researchers, this means the TB4/TB500 area is rich with mechanistic signal but still requires welldesigned human trials — particularly in the tendon, ligament, and muscle contexts where interest is highest. All compounds discussed are sold strictly for laboratory and research use only. Not for human consumption.
For research use only. Not for human consumption.